Emmanouil Simantirakis

Mr. Emmanouil Simantirakis


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
ECEvangelia-Eleni Christaki
Evangelia-Eleni Christaki
MPMarianna Politou
Marianna Politou
MAMarianna Antonelou
Marianna Antonelou
AAAngelos Athanasopoulos
Angelos Athanasopoulos
ESEmmanouil Simantirakis
Emmanouil Simantirakis
GVGeorge Vassilopoulos
George Vassilopoulos

8 September 2023 in Genes
Verified
Journal Article
Open access
PDF file
VLVasileios Lazaris
Vasileios Lazaris
ESEmmanouil Simantirakis
Emmanouil Simantirakis
ESEleana F. Stavrou
Eleana F. Stavrou
MVMeletios Verras
Meletios Verras
ASArgyro Sgourou
Argyro Sgourou
Aglaia AthanassiadouAglaia Athanassiadou
Aglaia Athanassiadou
β-Thalassemia is a subgroup of inherited blood disorders associated with mild to severe anemia with few and limited conventional therapy options. Lately, lentiviral vector-based gene therapy has been successfully applied for disease treatment. However, the current development of non-viral episomal vectors (EV), non-integrating and non-coding for viral proteins, may be helpful in generating valid alternatives to viral vectors. We constructed a non-viral, episomal vector pEPβ-globin for the physiological β-globin gene based on two human chromosomal elements: the scaffold or matrix attachment region (S/MAR), allowing for long nuclear retention and non-integration and the β-globin replication initiation region (IR), allowing for enhancement of replication and establishment. After nucleofections into K562 cells with a transfection efficiency of 24.62 ± 7.7%, the vector induces stable transfection and is detected in long-term cultures as a non-integrating, circular episome expressing the β-globin gene efficiently. Transfections into CD34+ cells demonstrate an average efficiency of 15.57 ± 11.64%. In the colony-forming cell assay, fluorescent colonies are 92.21%, which is comparable to those transfected with vector pEP-IR at 92.68%. Additionally, fluorescent colonies produce β-globin mRNA at a physiologically 3-fold higher level than the corresponding non-transfected cells. Vector pEPβ-globin provides the basis for the development of therapeutic EV for gene therapy of β-thalassemias.